Activation of the alpha1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint.
about
Constitutive activation of A(3) adenosine receptors by site-directed mutagenesisConstitutive activation of the neurotensin receptor 1 by mutation of Phe(358) in Helix sevenComputationally-predicted CB1 cannabinoid receptor mutants show distinct patterns of salt-bridges that correlate with their level of constitutive activity reflected in G protein coupling levels, thermal stability, and ligand binding.Identification of a ligand binding site in the human neutrophil formyl peptide receptor using a site-specific fluorescent photoaffinity label and mass spectrometry.Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases.Constitutive activation of the delta opioid receptor by mutations in transmembrane domains III and VII.Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β 2 AR.Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.Orthosteric binding of ρ-Da1a, a natural peptide of snake venom interacting selectively with the α1A-adrenoceptorResidues crucial for maintaining short paths in network communication mediate signaling in proteinsConformational changes of G protein-coupled receptors during their activation by agonist binding.New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues.Structure-function of alpha1-adrenergic receptors.Novel human alpha1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological functionHow and why do GPCRs dimerize?The seventh transmembrane domains of the delta and kappa opioid receptors have different accessibility patterns and interhelical interactions.Expression and function of G-protein-coupled receptors in the male reproductive tract.An overview of recent developments in GPCR modelling: methods and validation.Involvement of the first transmembrane segment of human α(2) -adrenoceptors in the subtype-selective binding of chlorpromazine, spiperone and spiroxatrine.Chlorpropamide upregulates antidiuretic hormone receptors and unmasks constitutive receptor signaling.Structural impact of the E113Q counterion mutation on the activation and deactivation pathways of the G protein-coupled receptor rhodopsin.Identification of a conserved switch residue responsible for selective constitutive activation of the beta2-adrenergic receptor.Phe310 in transmembrane VI of the alpha1B-adrenergic receptor is a key switch residue involved in activation and catecholamine ring aromatic bonding.Characteristics for a salt-bridge switch mutation of the alpha(1b) adrenergic receptor. Altered pharmacology and rescue of constitutive activity.Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6.Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists.The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling.G protein-coupled receptors. I. Diversity of receptor-ligand interactions.Molecular exploration of the α(1A)-adrenoceptor orthosteric site: binding site definition for epinephrine, HEAT and prazosin.Testing for inverse agonism with constitutive receptor systems.
P2860
Q28366534-0DC1BC02-A636-40CA-87AC-DDF500954E5EQ28573413-7455B550-0531-4387-88A6-443A1A11C85DQ30427185-D166B56C-685E-4276-BFE4-06A92BB8FE4FQ32066951-A346B50D-B3D2-4572-A980-BBC8F731ACB3Q33819076-2C861106-6F8D-450F-979C-4C982E2D8B3DQ33865332-1FD66DB5-39D9-4A24-B90C-716D16722A3AQ34167891-12ABC101-EC3D-4B52-AE45-0EA26B2237E7Q34168561-5D0E57AB-2F0B-441A-950C-70A8438819FFQ34918713-B2CD00A7-378D-4C60-9A20-56D4FFFF729BQ35193500-7BC1E06E-1B11-432A-B519-7F008A2842EBQ35588397-4438AB05-32CC-4A70-A327-BDCEF555174AQ36104901-F2000741-2F9D-4C99-82BC-4D9CAD897B46Q36628927-E8141161-0238-4CC1-9BBA-7AFBC0EE4BAAQ36632329-18E1F1E3-9A0B-47C7-B9CF-55DDC354DDF8Q37120246-BBC3CBF9-848D-422A-A4E3-2D4907ABF315Q37208197-066ABBA7-D20E-4C0E-B2C7-69B3F3EAB48EQ37590172-05DE0970-DF99-48FA-B72A-89A709AC998BQ38089807-72AF0E8E-27E3-453F-AD3F-20E447DDED52Q39264759-7B89088B-3AE0-4BAA-B207-22119AB7E085Q40880382-76F23B2D-537A-4172-84A2-04C884CE1BEDQ42071758-B271BF6A-6DAA-47B7-9A62-9D50DB38343AQ42450308-D26FEA96-04D2-4CC7-B35E-4D5594838961Q42472714-6E6448FC-6286-404E-88FE-D374054BE93EQ42480346-B4B2F13F-ABF9-4D51-B279-99E05C1CE165Q42819583-0CFF5305-AD25-4537-A2F0-3ADBA12B4CC7Q43594144-D5F9BE40-432D-4F7A-9C5E-22CDBB4E6BD8Q44226149-7078BA8C-6BD4-4A28-B227-4AC1E9EF83C4Q47892279-42BB00BC-5AE9-47D7-9519-241EFB832B7FQ51745770-591C491F-2BE0-4D1B-985B-2B49E2F8B327Q53600745-98B425EB-A25B-486B-B01D-198542565C84
P2860
Activation of the alpha1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Activation of the alpha1b-adre ...... elical salt bridge constraint.
@en
Activation of the alpha1b-adre ...... elical salt bridge constraint.
@nl
type
label
Activation of the alpha1b-adre ...... elical salt bridge constraint.
@en
Activation of the alpha1b-adre ...... elical salt bridge constraint.
@nl
prefLabel
Activation of the alpha1b-adre ...... elical salt bridge constraint.
@en
Activation of the alpha1b-adre ...... elical salt bridge constraint.
@nl
P2093
P356
P1476
Activation of the alpha1b-adre ...... elical salt bridge constraint.
@en
P2093
P304
28318-28323
P356
10.1074/JBC.271.45.28318
P407
P577
1996-11-01T00:00:00Z